Celsion Corp

Find Ratings Reports
CLSN : NASDAQ : Health Care
$1.82 -0.02 | -1.09%
Today's Range: 1.82 - 1.89
Avg. Daily Volume: 1077500.0
07/25/17 - 4:00 PM ET

Financial Analysis


CELSION CORP's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased. CELSION CORP has weak liquidity. Currently, the Quick Ratio is 0.51 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 60.11% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)0.130.13
EBITDA ($mil)0.00.0
EBIT ($mil)-4.82-5.18
Net Income ($mil)-5.16-5.72


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)4.4714.31
Total Assets ($mil)30.843.33
Total Debt ($mil)1.475.52
Equity ($mil)6.1115.31


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin-3854.4-4142.4
EBITDA Margin0.00.0
Operating Margin-3854.4-4142.4
Sales Turnover0.020.01
Return on Assets-69.8-48.86
Return on Equity-352.07-138.29
Debt Q1 FY17 Q1 FY16
Current Ratio0.521.54
Debt/Capital0.190.27
Interest Expense0.060.24
Interest Coverage-77.71-21.22


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)3.961.67
Div / share0.00.0
EPS-1.68-3.36
Book value / share1.549.15
Institutional Own % n/a n/a
Avg Daily Volume1478981.02723914.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.25 indicates a significant discount versus the S&P 500 average of 3.07 and a significant discount versus the industry average of 11.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CELSION CORP proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CLSN NM Peers 44.01   CLSN NM Peers 43.69

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CLSN's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CLSN's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CLSN NM Peers 27.93   CLSN NA Peers 0.55

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

CLSN's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CLSN 1.25 Peers 11.44   CLSN 22.35 Peers -7.96

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CLSN is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

CLSN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CLSN 15.21 Peers 190.63   CLSN 0.00 Peers 434.91

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CLSN is trading at a significant discount to its industry on this measurement.

 

Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.

The growth rate for CLSN is not available.

 

 

Latest Stock Upgrades/Downgrades